testosterone cypionate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
androgens/anabolic steroids 4454 58-20-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • testosterone cypionate
  • testosterone cyclopentylpropionate
cypionate ester of the androgenic hormone testosterone
  • Molecular weight: 412.61
  • Formula: C27H40O3
  • CLOGP: 6.97
  • LIPINSKI: 1
  • HAC: 3
  • HDO: 0
  • TPSA: 43.37
  • ALOGS: -5.98
  • ROTB: 5
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
June 23, 1978 FDA WATSON LABS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Metaplasia 307.77 22.61 48 3491 476 63485007
Idiopathic intracranial hypertension 265.64 22.61 55 3484 2876 63482607
Prostatic disorder 185.47 22.61 24 3515 46 63485437
Papilloedema 88.83 22.61 24 3515 3936 63481547
Off label use 85.88 22.61 142 3397 674320 62811163
Blood testosterone increased 73.76 22.61 12 3527 158 63485325
Cervix carcinoma stage IV 67.43 22.61 10 3529 68 63485415
Vaginal disorder 67.13 22.61 14 3525 754 63484729
Precocious puberty 63.43 22.61 11 3528 217 63485266
Enlarged clitoris 53.39 22.61 9 3530 149 63485334
Virilism 49.20 22.61 7 3532 34 63485449
Breast hyperplasia 47.27 22.61 9 3530 303 63485180
Priapism 40.61 22.61 7 3532 133 63485350
Infertility 39.04 22.61 9 3530 772 63484711
Adnexal torsion 38.08 22.61 8 3531 446 63485037
Endometrial hyperplasia 37.97 22.61 9 3530 871 63484612
Self-destructive behaviour 37.30 22.61 5 3534 14 63485469
Borderline serous tumour of ovary 37.30 22.61 5 3534 14 63485469
Accidental exposure to product by child 35.25 22.61 9 3530 1184 63484299
Multiple use of single-use product 33.25 22.61 9 3530 1483 63484000
Hormone level abnormal 32.95 22.61 10 3529 2473 63483010
Ovarian endometrioid carcinoma 30.79 22.61 4 3535 8 63485475
Vocal cord atrophy 30.17 22.61 4 3535 10 63485473
Vaginal lesion 29.88 22.61 6 3533 267 63485216
Renal infarct 28.87 22.61 8 3531 1439 63484044
Chorioretinopathy 28.11 22.61 7 3532 832 63484651
Hidradenitis 23.53 22.61 8 3531 2838 63482645
Atherosclerotic plaque rupture 23.44 22.61 3 3536 5 63485478
Renal artery fibromuscular dysplasia 22.77 22.61 3 3536 7 63485476

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product deposit 520.42 11.93 104 22001 304 34934522
Poor quality product administered 369.93 11.93 106 21999 1801 34933025
Polycythaemia 224.98 11.93 73 22032 1912 34932914
Blood testosterone increased 203.88 11.93 61 22044 1212 34933614
Injection site pain 153.11 11.93 154 21951 38851 34895975
Blood testosterone decreased 152.86 11.93 68 22037 4289 34930537
Multiple use of single-use product 130.36 11.93 32 22073 287 34934539
Liquid product physical issue 120.59 11.93 33 22072 469 34934357
Product quality issue 97.37 11.93 83 22022 16952 34917874
Product packaging quantity issue 92.55 11.93 31 22074 898 34933928
Clear cell renal cell carcinoma 75.04 11.93 28 22077 1119 34933707
Infertility male 72.30 11.93 18 22087 172 34934654
Precocious puberty 66.15 11.93 16 22089 134 34934692
Craniopharyngioma 64.20 11.93 18 22087 281 34934545
Mesenteric vein thrombosis 63.97 11.93 23 22082 826 34934000
Product dose omission issue 63.65 11.93 193 21912 119518 34815308
Muscle mass 61.77 11.93 17 22088 247 34934579
Haematocrit increased 61.60 11.93 29 22076 2084 34932742
Retinal neovascularisation 60.56 11.93 15 22090 140 34934686
Osteonecrosis 58.75 11.93 59 22046 14831 34919995
Oestradiol increased 55.80 11.93 12 22093 55 34934771
Secondary hypogonadism 55.05 11.93 16 22089 286 34934540
Deep vein thrombosis 52.76 11.93 123 21982 65125 34869701
Testicular atrophy 52.09 11.93 18 22087 574 34934252
Lymphoproliferative disorder 51.48 11.93 28 22077 2731 34932095
Drug abuse 50.99 11.93 158 21947 98938 34835888
Pituitary tumour benign 48.62 11.93 19 22086 862 34933964
Injection site swelling 47.92 11.93 47 22058 11480 34923346
Toxicity to various agents 46.86 11.93 35 22070 200327 34734499
Insulin-like growth factor increased 45.53 11.93 20 22085 1223 34933603
Product administered at inappropriate site 45.39 11.93 24 22081 2212 34932614
Death 43.96 11.93 119 21986 397930 34536896
Febrile neutropenia 43.64 11.93 16 22089 136833 34797993
Injection site mass 41.40 11.93 34 22071 6592 34928234
Neutropenia 41.22 11.93 24 22081 156754 34778072
General physical health deterioration 40.89 11.93 15 22090 128254 34806572
Pulmonary embolism 40.64 11.93 137 21968 89609 34845217
Product storage error 39.26 11.93 36 22069 8086 34926740
Insulin-like growth factor decreased 39.07 11.93 12 22093 261 34934565
Feeling abnormal 38.41 11.93 107 21998 63128 34871698
Idiopathic intracranial hypertension 38.27 11.93 15 22090 686 34934140
Acne fulminans 37.72 11.93 11 22094 199 34934627
Blood testosterone abnormal 37.32 11.93 13 22092 425 34934401
Haemoglobin increased 36.01 11.93 24 22081 3385 34931441
Performance enhancing product use 32.86 11.93 8 22097 69 34934757
Left ventricular hypertrophy 31.67 11.93 32 22073 8098 34926728
Product delivery mechanism issue 31.06 11.93 9 22096 159 34934667
Pituitary tumour recurrent 30.40 11.93 8 22097 97 34934729
Product physical consistency issue 29.56 11.93 12 22093 602 34934224
Blood oestrogen increased 29.45 11.93 7 22098 54 34934772
Septic shock 29.43 11.93 5 22100 71829 34862997
Erectile dysfunction 28.91 11.93 49 22056 20588 34914238
Product gel formation 28.90 11.93 5 22100 4 34934822
Anaemia 28.60 11.93 66 22039 233269 34701557
Renal infarct 28.58 11.93 15 22090 1361 34933465
Focal segmental glomerulosclerosis 28.25 11.93 17 22088 2008 34932818
Product container issue 27.74 11.93 12 22093 707 34934119
Myocardial fibrosis 27.61 11.93 14 22091 1183 34933643
Gynaecomastia 27.39 11.93 33 22072 10147 34924679
Hyperoestrogenism 27.06 11.93 5 22100 8 34934818
Fatigue 26.68 11.93 354 21751 370299 34564527
Intentional product misuse 26.53 11.93 76 22029 45535 34889291
Depression 26.07 11.93 126 21979 96972 34837854
Muscle hypertrophy 26.01 11.93 6 22099 40 34934786
Product administration error 25.86 11.93 41 22064 16303 34918523
Interstitial lung disease 25.76 11.93 5 22100 65277 34869549
Sleep apnoea syndrome 25.54 11.93 46 22059 20275 34914551
Renal artery thrombosis 25.50 11.93 9 22096 306 34934520
Phaeochromocytoma 25.19 11.93 8 22097 195 34934631
Portal vein thrombosis 24.85 11.93 20 22085 3768 34931058
Blood luteinising hormone decreased 24.75 11.93 7 22098 113 34934713
Product physical issue 24.72 11.93 17 22088 2524 34932302
Incorrect product administration duration 24.58 11.93 22 22083 4789 34930037
Pyomyositis 24.52 11.93 8 22097 213 34934613
Headache 24.40 11.93 213 21892 200422 34734404
Pancytopenia 24.38 11.93 15 22090 95142 34839684
Growth hormone-producing pituitary tumour 24.13 11.93 6 22099 57 34934769
Product colour issue 23.63 11.93 10 22095 558 34934268
Device malfunction 23.61 11.93 31 22074 10390 34924436
Spinal cord abscess 23.34 11.93 8 22097 249 34934577
Libido decreased 23.06 11.93 21 22084 4675 34930151
Cardiac death 23.05 11.93 12 22093 1071 34933755
Thrombocytopenia 22.71 11.93 40 22065 156207 34778619
Steatocystoma multiplex 22.70 11.93 4 22101 4 34934822
Circumstance or information capable of leading to medication error 22.43 11.93 14 22091 1765 34933061
Breast cancer 22.42 11.93 8 22097 281 34934545
Neoplasm recurrence 21.76 11.93 15 22090 2234 34932592
Drug-disease interaction 21.65 11.93 9 22096 480 34934346
Red blood cell count increased 21.29 11.93 13 22092 1576 34933250
Cerebral venous thrombosis 20.91 11.93 10 22095 744 34934082
Oligospermia 20.60 11.93 6 22099 108 34934718
Pituitary tumour 20.31 11.93 9 22096 562 34934264
Wrong technique in product usage process 20.00 11.93 59 22046 35927 34898899
Injection site erythema 19.99 11.93 36 22069 15863 34918963
Platelet count decreased 19.91 11.93 28 22077 119689 34815137
Pre-existing condition improved 19.85 11.93 15 22090 2577 34932249
Blood follicle stimulating hormone decreased 19.79 11.93 5 22100 51 34934775
No adverse event 19.37 11.93 44 22061 22883 34911943
Growth accelerated 18.85 11.93 4 22101 17 34934809
Completed suicide 18.35 11.93 21 22084 98147 34836679
Product contamination 18.29 11.93 9 22096 713 34934113
Priapism 18.26 11.93 19 22086 4975 34929851
Renal cell carcinoma 18.09 11.93 19 22086 5029 34929797
Glucose tolerance decreased 18.08 11.93 5 22100 74 34934752
Device dislocation 18.04 11.93 21 22084 6228 34928598
Pyrexia 18.03 11.93 130 21975 332883 34601943
Recalled product administered 17.56 11.93 8 22097 533 34934293
Acute kidney injury 17.52 11.93 117 21988 304871 34629955
Hypogonadism male 17.40 11.93 7 22098 343 34934483
Leukopenia 17.40 11.93 9 22096 62847 34871979
Disease progression 17.26 11.93 26 22079 108051 34826775
Injection site cellulitis 17.02 11.93 8 22097 573 34934253
Application site rash 16.83 11.93 9 22096 848 34933978
Anorgasmia 16.83 11.93 9 22096 848 34933978
Asthma exercise induced 16.54 11.93 5 22100 103 34934723
Hyperglycaemic hyperosmolar nonketotic syndrome 15.95 11.93 10 22095 1270 34933556
Optic ischaemic neuropathy 15.84 11.93 12 22093 2070 34932756
Anxiety 15.59 11.93 112 21993 99316 34835510
Product contamination physical 15.56 11.93 4 22101 44 34934782
Needle track marks 15.56 11.93 4 22101 44 34934782
Injection site infection 15.32 11.93 9 22096 1017 34933809
Amnesia 15.19 11.93 44 22061 26519 34908307
Muscle spasms 15.12 11.93 90 22015 74911 34859915
Aortic aneurysm 15.10 11.93 20 22085 6759 34928067
Thyrotoxic periodic paralysis 14.95 11.93 5 22100 144 34934682
Product closure issue 14.95 11.93 3 22102 9 34934817
Sleep disorder 14.87 11.93 49 22056 31639 34903187
Drug withdrawal syndrome 14.51 11.93 36 22069 19798 34915028
Open angle glaucoma 14.48 11.93 5 22100 159 34934667
Intracranial pressure increased 14.38 11.93 15 22090 3940 34930886
Blood thyroid stimulating hormone decreased 14.35 11.93 11 22094 1930 34932896
Malignant neoplasm progression 14.23 11.93 21 22084 88025 34846801
Arthralgia 14.13 11.93 167 21938 169874 34764952
Pneumonia 14.13 11.93 154 21951 362473 34572353
Injection site bruising 14.07 11.93 22 22083 8641 34926185
Intentional dose omission 14.04 11.93 14 22091 3486 34931340
Acne conglobata 13.91 11.93 3 22102 14 34934812
Cardio-respiratory arrest 13.76 11.93 9 22096 55264 34879562
Intentional misuse of drug delivery system 13.74 11.93 3 22102 15 34934811
Blood testosterone free decreased 13.68 11.93 4 22101 73 34934753
Multiple organ dysfunction syndrome 13.65 11.93 17 22088 76549 34858277
Suicidal ideation 13.53 11.93 56 22049 40332 34894494
Incorrect dose administered 13.43 11.93 56 22049 40459 34894367
Blood growth hormone increased 13.43 11.93 6 22099 382 34934444
Retinal vein occlusion 13.28 11.93 10 22095 1709 34933117
C-reactive protein increased 13.21 11.93 9 22096 54089 34880737
Mucosal inflammation 13.20 11.93 4 22101 38618 34896208
Product contamination microbial 13.16 11.93 7 22098 653 34934173
Cholelithiasis 13.04 11.93 36 22069 21112 34913714
Hypogonadism 12.90 11.93 11 22094 2244 34932582
Cardiomyopathy 12.82 11.93 31 22074 16777 34918049
Stevens-Johnson syndrome 12.77 11.93 33 22072 18606 34916220
Exaggerated startle response 12.75 11.93 3 22102 22 34934804
Expired product administered 12.74 11.93 13 22092 3328 34931498
Decreased appetite 12.72 11.93 58 22047 166334 34768492
Azoospermia 12.69 11.93 6 22099 435 34934391
Myalgia 12.19 11.93 93 22012 84017 34850809
Gastric hypomotility 12.17 11.93 4 22101 109 34934717
Therapeutic response unexpected 12.15 11.93 22 22083 9735 34925091
Injection site reaction 12.12 11.93 26 22079 13007 34921819
Depressed level of consciousness 12.06 11.93 6 22099 42835 34891991
Device delivery system issue 11.97 11.93 6 22099 495 34934331
Needle issue 11.94 11.93 17 22088 6148 34928678

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Idiopathic intracranial hypertension 348.56 12.29 92 19066 3130 79722100
Metaplasia 299.94 12.29 59 19099 503 79724727
Polycythaemia 260.41 12.29 68 19090 2216 79723014
Blood testosterone increased 230.65 12.29 53 19105 999 79724231
Product deposit 203.59 12.29 43 19115 538 79724692
Prostatic disorder 134.36 12.29 40 19118 2120 79723110
Blood testosterone decreased 130.58 12.29 40 19118 2337 79722893
Precocious puberty 118.56 12.29 25 19133 310 79724920
Poor quality product administered 109.97 12.29 39 19119 3606 79721624
Clear cell renal cell carcinoma 90.97 12.29 31 19127 2545 79722685
Drug abuse 79.26 12.29 141 19017 162550 79562680
Craniopharyngioma 76.29 12.29 18 19140 382 79724848
Deep vein thrombosis 69.73 12.29 113 19045 120806 79604424
Acne fulminans 69.72 12.29 15 19143 206 79725024
Infertility male 67.73 12.29 13 19145 96 79725134
Lymphoproliferative disorder 67.55 12.29 31 19127 5584 79719646
Testicular atrophy 67.14 12.29 16 19142 355 79724875
Cervix carcinoma stage IV 64.97 12.29 12 19146 70 79725160
Secondary hypogonadism 62.06 12.29 15 19143 354 79724876
Product quality issue 62.06 12.29 57 19101 33883 79691347
Retinal neovascularisation 61.08 12.29 13 19145 169 79725061
Mesenteric vein thrombosis 60.68 12.29 21 19137 1806 79723424
Renal infarct 59.81 12.29 23 19135 2668 79722562
Pulmonary embolism 59.56 12.29 129 19029 171525 79553705
Muscle mass 58.65 12.29 15 19143 449 79724781
Left ventricular hypertrophy 52.46 12.29 33 19125 11158 79714072
Vaginal disorder 51.65 12.29 14 19144 527 79724703
Osteonecrosis 50.68 12.29 49 19109 31046 79694184
Erectile dysfunction 48.91 12.29 35 19123 14629 79710601
Focal segmental glomerulosclerosis 48.49 12.29 21 19137 3300 79721930
Haematocrit increased 47.67 12.29 22 19136 4012 79721218
Gynaecomastia 47.31 12.29 27 19131 7654 79717576
Virilism 46.87 12.29 8 19150 27 79725203
Injection site pain 45.50 12.29 98 19060 129740 79595490
Performance enhancing product use 45.41 12.29 9 19149 80 79725150
Priapism 45.36 12.29 22 19136 4483 79720747
Ovarian endometrioid carcinoma 45.13 12.29 7 19151 10 79725220
Multiple use of single-use product 44.25 12.29 14 19144 910 79724320
Papilloedema 44.09 12.29 24 19134 6209 79719021
Product administered at inappropriate site 41.85 12.29 20 19138 3945 79721285
Pituitary tumour benign 39.95 12.29 17 19141 2559 79722671
Steatocystoma multiplex 39.85 12.29 6 19152 6 79725224
Pituitary tumour recurrent 38.46 12.29 9 19149 184 79725046
Oestradiol increased 37.95 12.29 8 19150 99 79725131
Portal vein thrombosis 37.28 12.29 21 19137 5806 79719424
Enlarged clitoris 36.79 12.29 6 19152 14 79725216
Myocardial fibrosis 35.75 12.29 14 19144 1704 79723526
Intracranial pressure increased 35.19 12.29 23 19135 8299 79716931
Insulin-like growth factor increased 34.49 12.29 14 19144 1872 79723358
Haemoglobin increased 33.65 12.29 20 19138 6112 79719118
Blood oestrogen increased 33.41 12.29 7 19151 84 79725146
Oligospermia 32.06 12.29 6 19152 38 79725192
Endometrial hyperplasia 31.97 12.29 10 19148 626 79724604
Accidental exposure to product by child 31.62 12.29 15 19143 2911 79722319
Ophthalmic vein thrombosis 31.52 12.29 8 19150 232 79724998
Infertility 31.01 12.29 10 19148 691 79724539
General physical health deterioration 30.46 12.29 14 19144 275224 79450006
Vocal cord atrophy 30 12.29 5 19153 14 79725216
Borderline serous tumour of ovary 30 12.29 5 19153 14 79725216
Neutropenia 29.78 12.29 16 19142 287694 79437536
Product dose omission issue 29.71 12.29 128 19030 247409 79477821
Injection site mass 29.54 12.29 30 19128 20154 79705076
Growth hormone-producing pituitary tumour 29.37 12.29 6 19152 63 79725167
Adnexal torsion 27.82 12.29 8 19150 375 79724855
Renal cell carcinoma 27.38 12.29 18 19140 6560 79718670
Feeling abnormal 27.07 12.29 92 19066 159107 79566123
Cardiac death 26.46 12.29 11 19147 1563 79723667
Neoplasm recurrence 26.45 12.29 15 19143 4199 79721031
Liquid product physical issue 25.97 12.29 10 19148 1164 79724066
Renal artery thrombosis 25.73 12.29 8 19150 491 79724739
Toxicity to various agents 25.16 12.29 39 19119 421501 79303729
Contraindicated product administered 24.89 12.29 4 19154 157534 79567696
Intentional product misuse 24.79 12.29 64 19094 95101 79630129
Breast hyperplasia 24.57 12.29 6 19152 148 79725082
Device malfunction 24.56 12.29 28 19130 21420 79703810
Vaginal lesion 24.46 12.29 6 19152 151 79725079
Azoospermia 24.16 12.29 6 19152 159 79725071
Rheumatoid arthritis 24.01 12.29 10 19148 208460 79516770
Pyomyositis 23.96 12.29 8 19150 617 79724613
Suicidal ideation 23.78 12.29 55 19103 76285 79648945
Blood luteinising hormone decreased 23.77 12.29 6 19152 170 79725060
Phaeochromocytoma 23.45 12.29 8 19150 659 79724571
Drug-disease interaction 23.12 12.29 9 19149 1078 79724152
Glucose tolerance decreased 22.70 12.29 5 19153 77 79725153
Optic ischaemic neuropathy 22.62 12.29 12 19146 2949 79722281
Spinal cord abscess 22.35 12.29 7 19151 440 79724790
Hidradenitis 22.31 12.29 12 19146 3032 79722198
Off label use 22.31 12.29 323 18835 906892 78818338
Depression 22.20 12.29 107 19051 216683 79508547
Blood testosterone abnormal 21.73 12.29 6 19152 242 79724988
Self-destructive behaviour 21.42 12.29 4 19154 25 79725205
Cardiomyopathy 20.96 12.29 30 19128 28744 79696486
Febrile neutropenia 20.92 12.29 15 19143 230984 79494246
Injection site swelling 20.58 12.29 39 19119 47093 79678137
Muscle hypertrophy 20.49 12.29 5 19153 123 79725107
Irritability 20.43 12.29 36 19122 41108 79684122
Completed suicide 19.71 12.29 18 19140 245749 79479481
Septic shock 19.66 12.29 3 19155 122798 79602432
Hyperglycaemic hyperosmolar nonketotic syndrome 19.50 12.29 10 19148 2293 79722937
Blood testosterone free decreased 19.49 12.29 4 19154 43 79725187
Exaggerated startle response 19.49 12.29 4 19154 43 79725187
Drug withdrawal syndrome 19.38 12.29 32 19126 34686 79690544
Aortic aneurysm 19.07 12.29 16 19142 8430 79716800
Atherosclerotic plaque rupture 19.06 12.29 3 19155 5 79725225
Anaemia 19.00 12.29 50 19108 444965 79280265
Gender dysphoria 18.79 12.29 4 19154 52 79725178
Libido decreased 18.43 12.29 13 19145 5308 79719922
Infusion related reaction 18.30 12.29 17 19141 230220 79495010
Drug intolerance 18.19 12.29 22 19136 264097 79461133
Cerebral venous thrombosis 17.82 12.29 10 19148 2743 79722487
Needle track marks 17.52 12.29 4 19154 73 79725157
Product physical consistency issue 17.52 12.29 7 19151 898 79724332
Diastolic hypertension 17.08 12.29 4 19154 82 79725148
Cortisol increased 17.08 12.29 6 19152 539 79724691
Sleep apnoea syndrome 16.94 12.29 31 19127 36447 79688783
Lower respiratory tract infection 16.93 12.29 5 19153 129215 79596015
Treatment failure 16.88 12.29 10 19148 170476 79554754
Myocardial infarction 16.81 12.29 88 19070 184041 79541189
Intentional misuse of drug delivery system 16.80 12.29 3 19155 14 79725216
Insulin-like growth factor decreased 16.67 12.29 6 19152 579 79724651
Product use in unapproved indication 16.62 12.29 110 19048 250249 79474981
Stevens-Johnson syndrome 16.59 12.29 32 19126 39134 79686096
Thrombosis 16.45 12.29 51 19107 84049 79641181
Endometrial adenocarcinoma 16.36 12.29 7 19151 1068 79724162
Borderline ovarian tumour 16.17 12.29 3 19155 18 79725212
Retinal vein occlusion 16.08 12.29 10 19148 3313 79721917
Vein collapse 16.03 12.29 7 19151 1121 79724109
Growth accelerated 16.03 12.29 3 19155 19 79725211
Product administration error 15.99 12.29 28 19130 31818 79693412
Coronary artery dissection 15.94 12.29 7 19151 1137 79724093
Blood growth hormone increased 15.32 12.29 6 19152 730 79724500
Anorgasmia 15.32 12.29 7 19151 1247 79723983
Ovarian necrosis 15.31 12.29 3 19155 25 79725205
Asthma exercise induced 15.06 12.29 4 19154 139 79725091
Acne conglobata 15.00 12.29 3 19155 28 79725202
Hormone level abnormal 14.97 12.29 8 19150 1994 79723236
Blood follicle stimulating hormone decreased 14.93 12.29 4 19154 144 79725086
Eye colour change 14.72 12.29 5 19153 406 79724824
Thyrotoxic periodic paralysis 14.59 12.29 4 19154 157 79725073
Recalled product administered 14.51 12.29 6 19152 841 79724389
Application site rash 14.50 12.29 8 19150 2124 79723106
Open angle glaucoma 14.31 12.29 5 19153 442 79724788
Prescription drug used without a prescription 14.20 12.29 10 19148 4075 79721155
Gastric hypomotility 13.90 12.29 4 19154 188 79725042
Product contamination microbial 13.87 12.29 6 19152 940 79724290
Acne 13.77 12.29 24 19134 27166 79698064
Nasopharyngitis 13.73 12.29 25 19133 253856 79471374
Hepatic artery aneurysm 13.63 12.29 3 19155 46 79725184
Glossodynia 13.54 12.29 4 19154 103333 79621897
Ventricular hypertrophy 13.36 12.29 12 19146 6926 79718304
Myalgia 13.19 12.29 83 19075 185558 79539672
Astrocytoma 13.17 12.29 4 19154 227 79725003
Myoglobinuria 13 12.29 6 19152 1094 79724136
Fibromuscular dysplasia 12.89 12.29 4 19154 244 79724986
Dissociative identity disorder 12.79 12.29 3 19155 62 79725168
Stomatitis 12.67 12.29 10 19148 146747 79578483
Metabolic syndrome 12.64 12.29 8 19150 2732 79722498
Acute myocardial infarction 12.63 12.29 44 19114 76992 79648238
Accidental exposure to product 12.55 12.29 25 19133 31297 79693933
Shunt malfunction 12.54 12.29 4 19154 267 79724963
Hypothalamo-pituitary disorder 12.53 12.29 6 19152 1188 79724042
Ovarian cancer stage II 12.44 12.29 3 19155 70 79725160
Drug hypersensitivity 12.43 12.29 34 19124 298882 79426348
Pituitary tumour 12.40 12.29 6 19152 1216 79724014
Anxiety 12.38 12.29 102 19056 248410 79476820

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA CS M0001109 Androstanes
FDA MoA N0000000146 Androgen Receptor Agonists
MeSH PA D000728 Androgens
MeSH PA D006728 Hormones
FDA EPC N0000175824 Androgen
CHEBI has role CHEBI:50113 androgene
CHEBI has role CHEBI:75771 Mus musculus metabolites
CHEBI has role CHEBI:77746 Homo sapiens metabolite
CHEBI has role CHEBI:83056 Daphnia magna metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Deficiency of testosterone biosynthesis indication 38825009
Male hypogonadism indication 48723006
Menopausal flushing indication 198436008
Undescended testicle indication 204878001 DOID:11383
Delayed puberty indication 400003000
Klinefelter's syndrome, XXY indication 405769009
Hormone receptor positive malignant neoplasm of breast indication 417181009
LHRH Deficiency indication
Hyperlipoproteinemia contraindication 3744001 DOID:1168
Gynecomastia contraindication 4754008 DOID:12698
Hypocalcemia contraindication 5291005
Hypercholesterolemia contraindication 13644009
Myocardial infarction contraindication 22298006 DOID:5844
Chloasma contraindication 36209000
Migraine contraindication 37796009 DOID:6364
Hypertensive disorder contraindication 38341003 DOID:10763
Disorder of gallbladder contraindication 39621005 DOID:0060262
Hypothyroidism contraindication 40930008 DOID:1459
Body fluid retention contraindication 43498006
Thrombosis of retinal vein contraindication 46085004
Humoral hypercalcemia of malignancy contraindication 47709007
Chronic heart failure contraindication 48447003
Dementia contraindication 52448006
Hepatic porphyria contraindication 55056006 DOID:3133
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Heart disease contraindication 56265001 DOID:114
Thrombophlebitis contraindication 64156001 DOID:3875
Intermenstrual bleeding - irregular contraindication 64996003
Diabetes mellitus contraindication 73211009 DOID:9351
Sleep apnea contraindication 73430006 DOID:0050847
Epilepsy contraindication 84757009 DOID:1826
Breast lump contraindication 89164003
Kidney disease contraindication 90708001 DOID:557
Uterine leiomyoma contraindication 95315005 DOID:13223
Neoplasm of prostate contraindication 126906006 DOID:10283
Deep venous thrombosis contraindication 128053003
Endometriosis contraindication 129103003
Mammography abnormal contraindication 168750009
Asthma contraindication 195967001 DOID:2841
Cerebrovascular accident contraindication 230690007
Pulmonary thromboembolism contraindication 233935004
Thrombophilia contraindication 234467004 DOID:2452
Disease of liver contraindication 235856003 DOID:409
Endometrial carcinoma contraindication 254878006 DOID:2871
Benign prostatic hyperplasia contraindication 266569009
Edema contraindication 267038008
Chorea contraindication 271700006
Pregnancy, function contraindication 289908002
Hypertriglyceridemia contraindication 302870006
Functional visual loss contraindication 313165001
Malignant tumor of ovary contraindication 363443007 DOID:2394
Thromboembolic disorder contraindication 371039008
Cardiovascular event risk contraindication 395112001
Breastfeeding (mother) contraindication 413712001
Chronic lung disease contraindication 413839001
Disorder of coronary artery contraindication 414024009
Obesity contraindication 414916001 DOID:9970
Estrogen receptor positive tumor contraindication 416053008
Family history of malignant neoplasm of breast contraindication 429740004
Hypertensive urgency contraindication 443482000
Carcinoma of female breast contraindication 447782002
Smokes tobacco daily contraindication 449868002
Breast Carcinoma in Males contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Androgen receptor Nuclear hormone receptor AGONIST CHEMBL CHEMBL

External reference:

IDSource
D00957 KEGG_DRUG
4017483 VUID
N0000179263 NUI
4017483 VANDF
4017484 VANDF
CHEBI:9463 CHEBI
CHEBI:17347 CHEBI
TES PDB_CHEM_ID
CHEMBL1201101 ChEMBL_ID
DB13943 DRUGBANK_ID
M0XW1UBI14 UNII
441404 PUBCHEM_CID
DB00624 DRUGBANK_ID
10379 RXNORM
2966 MMSL
2990 MMSL
5552 MMSL
5553 MMSL
d00558 MMSL
001245 NDDF
001246 NDDF
109033004 SNOMEDCT_US
109034005 SNOMEDCT_US
43688007 SNOMEDCT_US
C0076181 UMLSCUI
C0039601 UMLSCUI
1900 INN_ID
6013 PUBCHEM_CID
D013739 MESH_DESCRIPTOR_UI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Depo-Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0009-0085 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 28 sections
Depo-Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0009-0086 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 28 sections
Depo-Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0009-0347 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 28 sections
Depo-Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 0009-0417 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 28 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9005 INJECTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9659 INJECTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9659 INJECTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9726 INJECTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0143-9726 INJECTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6557 INJECTION, SOLUTION 100 mg INTRAMUSCULAR ANDA 28 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6562 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 28 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0409-6562 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 28 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0517-1830 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 26 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0517-1830 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 26 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0574-0820 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 27 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0574-0827 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0591-4128 INJECTION 200 mg INTRAMUSCULAR ANDA 27 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 0591-4128 INJECTION 200 mg INTRAMUSCULAR ANDA 27 sections
testosterone cypionate HUMAN PRESCRIPTION DRUG LABEL 1 47781-910 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
testosterone cypionate HUMAN PRESCRIPTION DRUG LABEL 1 47781-910 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
testosterone cypionate HUMAN PRESCRIPTION DRUG LABEL 1 47781-911 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
testosterone cypionate HUMAN PRESCRIPTION DRUG LABEL 1 47781-911 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-0330 INJECTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4147 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 28 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4147 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 28 sections
Testosterone Cypionate Human Prescription Drug Label 1 50090-4446 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 26 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4920 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 50090-4921 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 25 sections
Testosterone Cypionate HUMAN PRESCRIPTION DRUG LABEL 1 52536-625 INJECTION 200 mg INTRAMUSCULAR ANDA 28 sections
Depo-Testosterone HUMAN PRESCRIPTION DRUG LABEL 1 54868-0216 INJECTION, SOLUTION 200 mg INTRAMUSCULAR ANDA 26 sections